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DObjectives: Transcatheter aortic valve implantation (TAVI) has become an important therapeutic option for
high-risk patients with severe aortic valve stenosis. Patient–prosthesis mismatch (P-PM) is an important deter-
minant of morbidity and mortality after open aortic valve replacement. The objective of our study was to eval-
uate P-PM incidence and its impact on survival in a large cohort of patients treated with TAVI.
Methods and Results:We retrospectively analyzed transesophageal echocardiographic data of 278 consecutive
patients (Society of Thoracic Surgeons score 18.5  15.3, age 80  8 years) who underwent transapical TAVI
with Edwards Sapien valves between April 2008 andMarch 2011. Effective orifice area was calculated using the
continuity equation and indexed with body surface area (iEOA). P-PM was stratified as severe (iEOA<0.65
cm2/cm2) and moderate (iEOA, 0.65-0.85 cm2/m2). Midterm survival (up to 30 months) was analyzed by
Kaplan-Meier curves and log–rank tests. There was no P-PM in 181 (65.1%) patients; moderate P-PM was
found in 76 (27.3%) patients and severe P-PM in 21 (7.6%). Thirty-day survival was 96.0%, 97.3%, and
90.5%. The 3-month survival was 91%, 90%, and 66%, respectively (P ¼ .0013). Combination of severe
P-PM with peak pressure gradients greater than 10 mm Hg further reduced the 3-month survival to 48%. Ad-
ditionally, mean survival time in patients with an ejection fraction less than 50%was significantly shorter than in
patients with an ejection fraction greater than 50% (20.8  1.5 vs 24.1  0.8 months; P ¼ .027).
Conclusions: P-PM is found in patients undergoing transapical TAVI. Severe mismatch is accompanied by high
early mortality, especially when combined with increased pressure gradients. (J Thorac Cardiovasc Surg
2013;145:391-7)Aortic valve stenosis is an important cause of cardiac mor-
bidity and mortality in elderly patients.1 Replacement of the
aortic valvewith a prosthesis is the only treatment having an
impact on mortality in symptomatic patients. Despite tech-
nical developments to optimize valve prostheses, the rheo-
logic properties of prostheses are not comparable with
those of native human valves, and aortic stenosis is traded
for prosthesis hemodynamics. This patient–prosthesis mis-
match (P-PM) was described by Rahimtoola2 in 1978 as
consisting of the effective prosthetic valve area less than
that of a normal human valve. Nowadays, P-PM is assumed
when the effective orifice area (EOA), determined with the
continuity equation, of a normally functioning prosthesis is
too small in relation to the patient’s body size and results in
increased transprosthetic pressure gradients during hemo-
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is EOA indexed with body surface area (iEOA). Patients
with severe P-PM have an iEOA less than 0.65 cm2/m2
and those with moderate P-PM an iEOA of between 0.65
and 0.85 cm2/m2.3 The incidence of severe P-PM after sur-
gical aortic valve replacement (AVR) is 2% to 11% and of
moderate P-PM 20% to 70% and is related to adverse clin-
ical outcome.4
Transcathether aortic valve implantation has become
a therapy option in high-risk patients with severe aortic ste-
nosis.5-7 The procedure reduces the surgical risk and enables
easier and faster postoperative recovery. Periprocedural
clinical decision making during transcatheter aortic valve
implantation (TAVI) is based on various imaging methods
including computed tomography, echocardiography, and
angiography.8 Among these imaging techniques, transeso-
phageal echocardiography (TEE) seems to be superior for
preprocedural geometric measurements, risk assessment,
rapid diagnosis of intraprocedural complications, and as-
sessment of functional hemodynamic characteristics after
valve implantation.9 In our institution exact postprocedural
echocardiographic assessment of left ventricular (LV) func-
tion, valve function, geometric orifice area (GOA), and EOA
is included in the standard TEE evaluation immediately after
TAVI.6,8,10
The aim of this study was to evaluate the incidence of
P-PM in a large cohort of patients treated with transapicalrdiovascular Surgery c Volume 145, Number 2 391
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
EF ¼ ejection fraction
EOA ¼ effective orifice area
iEOA ¼ effective orifice area indexed with
body surface area
GOA ¼ geometric orifice area
LV ¼ left ventricle (ventricular)
LVEDV ¼ left ventricular end-diastolic volume
LVEF ¼ left ventricular ejection fraction
LVESV ¼ left ventricular end-systolic volume
LVOT ¼ left ventricular outflow tract
P-PM ¼ patient–prosthesis mismatch
TAVI ¼ transcatheter aortic valve implantation
TEE ¼ transesophageal echocardiography
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DTAVI with a balloon-expandable transcatheter valve and to
analyze the impact of P-PM and periprocedurally acquired
echocardiographic parameters on early and midterm
survival.METHODS
Patients
Between April 2008 and March 2011, we enrolled in the study 278 pa-
tients treated with TAVI using Edwards Sapien valves (Edwards Lifescien-
ces, Irvine, Calif). Written informed consent was obtained from all
patients. The study was approved by our institutional review committee.
Our initial results, technical considerations, institutional policies, and early
outcomes have been published elsewhere.6,8,10 Follow-up was between 1
and 30 months with a total of 3916 patient-months and was complete in
all patients. Except for the few hospital deaths, survival data were obtained
from the public register of residence.
TAVI Procedure
The valve was implanted through a mini left anterior thoracotomy via
the transapical route using balloon-expandable transcatheter stent–pros-
thetic xenograft valves 23 or 26 mm in diameter with their delivering sys-
tem (both Edwards Sapien THV, Edwards Lifesciences). All procedures
were performed by our team of cardiac surgeons, a cardiologist, and anes-
thesiologists in our hybrid operation room equipped with a monoplane
angiography system. A perfusionist and a heart–lung machine were at
stand-by in the operating room. The surgical technique as described in de-
tail by Walther and colleagues11 was used with some modifications. The
most important modification was slow and gradual valve deployment (as
opposed to rapid deployment by forced inflation of the balloon in the orig-
inal technique) supported by simultaneous angiographic visualization.10
This visualization of the aortic root during slow valve deployment enables
optimal positioning of the valve with perfect presentation of the relation-
ships among the prosthetic valve, the aortic valve annulus, aortic cusps,
and coronary arteries. The valvewas always implanted during a short phase
of rapid ventricular pacing. Additionally, the main steps of the procedure
were monitored by intraprocedural TEE, namely, visualization and correct
positioning of the guide wire across the native aortic valve via the transap-
ical path, transapical introduction of the 14Fr soft sheath and then the 26Fr
delivery system, assessment of ventricular function after rapid pacing and
balloon valvuloplasty, and assessment of the implanted valve, the coronary392 The Journal of Thoracic and Cardiovascular Surgarteries, and global and regional LVand right ventricular function immedi-
ately after implantation.
Valve Size Selection
The size of the valve used was determined according to the diameter of
the native aortic valve annulus and aortic root morphology assessed by in-
traoperative TEE. We chose a valve size of 23 mm for aortic valve annuli
smaller than 21 mm and 26 mm for annuli between 21 mm and 24 mm. In
borderline cases, the decision was made on an individual basis, taking into
account additional factors such as the distance from the annulus to the cor-
onary artery ostia, the shape of the annulus (oval vs circular), the amount of
calcification in the leaflets, or aortic diameters at the level of the sinuses of
Valsalva.
Intraprocedural and Postprocedural TEE
Measurements
TEEwas used to quantify preprocedural and postprocedural aortic valve
geometry and hemodynamics. According to the recommendations of the
American Society of Echocardiography,12 the standard TEE views for as-
sessment of LV function and aortic valve morphology and hemodynamics
were acquired and digitally stored. All examinations were performed with
the same type of echocardiography equipment (Vivid I; GEVingmedUltra-
sound, Horten, Norway) during steady state periods after induction of an-
esthesia, after valve implantation, and at the end of the procedure before
termination of anesthesia.
Analyses of the Echocardiographic Data
A retrospective quantitative analysis of periprocedural echocardio-
graphic data was performed by an experienced echocardiographer who
was blinded to outcome parameters using the Echopac work station (Echo-
pac; GE Vingmed Ultrasound). Measurements were averaged from 3 to 5
beats.
LV Function
For quantification of LV systolic function, we applied the Simpson bi-
plane method and calculated end-diastolic and end-systolic volumes and
the resulting ejection fraction.
Pressure Gradients
To quantify peak and mean pressure gradients across the aortic valve,
we traced the outer edge of the Doppler signal curve across the aortic valve.
The maximal pressure gradient is calculated from the maximum velocity
(Vmax) using a simplified Bernoulli equation: DPmax ¼ 4 3 Vmax2.
The mean gradient is calculated by averaging the instantaneous gradients
during the whole ejection period.
EOA
To quantify the EOA, we used the continuity equation based on the con-
cept that the stroke volume in the left ventricular outflow tract (LVOT) and
across the aortic valve is equal. Stroke volume in Doppler echocardiogra-
phy is calculated as cross-sectional area times the average flow velocity
during the ejection period (velocity time integral, VTI). The cross-
sectional area (CSA) in the LVOT is calculated using the LVOT diameter.
We traced the dense velocity curve in the LVOT and the outer edge of the
velocity curve across the aortic valve (AV). The resulting values were in-
cluded in the continuity equation to obtain the EOA: EOA ¼ VTI
LVOT 3 CSA LVOT/VTI AV.
GOA
GOAwas quantified by planimetry using the edge of the calcified or im-
planted valve from the aortic valve short-axis view in midsystole.ery c February 2013
TABLE 1. Echocardiographic findings before and after TAVI
Variable Pre-TAVI Post-TAVI P value
EF (%) 53  17 59  15 <.00001
LVEDV (mL) 88  113 68  32 .002
LVESV (mL) 41  32 31  24 <.00001
LVOT SV (mL) 49  17 51  19 .08
LVOT CO (L/min) 2.8  1.0 3.7  1.4 <.00001
HR (beats/min) 58  16 74  17 <.00001
LVOT Vmax (m/s) 0.71  0.21 0.98  0.28 <.00001
dPmax (mm Hg) 63  23 10.5  5.8 <.00001
dPmean (mm Hg) 38  14 5.4  3.0 <.00001
AV annulus (mm) 21.8  1.6 17.9  1.6 <.00001
GOA (cm2) 0.70  2.0 2.06  0.35 <.00001
EOA (cm2) 0.51  0.17 1.76  0.44 <.00001
iEOA (cm2/m2) 0.28  1.0 0.98  0.26 <.00001
EOA/GOA 0.76  0.24 0.85  0.18 <.00001
Ejection fractions and left ventricular volumes were calculated by the biplane
method. All data are means  standard deviation. P values are derived from paired
t tests. TAVI, Transcatheter aortic valve implantation; EF, ejection fraction; LVEDV
and LVESV, left ventricular end-diastolic and end-systolic volumes; LVOT SV and
LVOT CO, stroke volume and cardiac output calculated from left ventricular outflow
tract diameter and mean blood flow velocity;HR, heart rate; LVOT Vmax, peak LVOT
blood flow velocity; dPmax, peak transvalvular pressure gradient; dPmean, mean
transvalvular pressure gradient; AVannulus, aortic valve annulus diameter;GOA, geo-
metric orifice area; EOA, effective orifice area; iEOA, indexed effective orifice area.




The EOAwas indexed by body surface area (iEOA) to consider the car-
diac output requirements of the patients. Moderate P-PMwas considered to
be present if iEOAwas from 0.65 cm2/m2 to 0.85 cm2/m2, and severe P-PM
was defined as iEOA smaller than 0.65 cm2/m2.3
Statistics
Preprocedural and postprocedural echocardiographic data are presented
as mean standard deviation. Changes were analyzed by paired t tests. Pa-
tient survival was analyzed using Kaplan-Meier curves and differences be-
tween groups were assessed by log–rank tests with Holm-Sidak all pairwise
comparisons for P-PM. Patients were assigned to groups according to clin-
ically established cutoff values of echocardiographic parameters (iEOA,
LV ejection fraction [LVEF], heart rate) or according to optimal cutoff
values derived from receiver operating characteristics curves (LV end-
diastolic volume [LVEDV], LV end-systolic volume [LVESV]). Multivar-
iate survival analyses were performed for 3-month and 30-month survivals
using a Cox regression proportional hazards model. Independent predictors
for severe P-PM were identified by multivariate logistic regression. Differ-
ences among groups with no, moderate, and severe P-PMwere assessed by
the Kruskal-Wallis test followed by the Dunn post hoc multiple compari-
sons or by c2 tests.
RESULTS
Patient Cohort
Of 301 patients who underwent TAVI, 7 received a second
valve during the same procedure (to treat significant para-
prosthetic leakage or transvalvular regurgitation after im-
plantation of the first Edwards Sapien valve) and 16
underwent so-called ‘‘valve-in-valve’’ transapical TAVI13
owing to degeneration of a previously surgically implanted
biological aortic valve prosthesis. These 23 patientswere ex-
cluded from the study. In total, data from 278 patients were
analyzed. The mean patient age was 80 8 years, the mean
logistic EuroSCOREwas 38.0% 20.3%, and The Society
of Thoracic Surgeons score was 18.5% 15.3%. A 23-mm
valvewas implanted in 91 patients and a 26-mmvalve in 187.
LVEF
LV systolic function improved immediately after TAVI
(Table 1). Biplane ejection fraction (EF) increased from
53%  17% to 59%  15% (P<.00001). Both LVEDV
and LVESV decreased, which was slightly more noticeable
in LVESV (LVEDV, 24%, P ¼ .002; LVESV, 28%,
P<.00001). Correlation analyses revealed a strong inverse
dependence of LVESVon LVEF (R ¼0.77; P<.00001).
Transaortic Pressure Gradients
Periprocedural changes in aortic valve hemodynamics as
assessed by TEE are also given in Table 1. Peak and mean
transaortic pressure gradients decreased from 63  23 and
38  14 mm Hg to 10.5  5.8 and 5.4  3.0 mm Hg,
respectively.
EOA
After TAVI, EOA increased from a preimplant value of
0.51  0.17 to a postimplant value of 1.76  0.44 cm2.The Journal of Thoracic and CaEOA was only weakly related to preprocedural annulus
size (R¼ 0.31; P<.00001) or severity of preprocedural ste-
nosis (preprocedural EOA; R ¼ 0.14; P ¼ .023).GOA
Postprocedurally assessed GOA correlated reasonably
with EOA (R ¼ 0.57; P< .00001) and was greater than
EOAwith a mean ratio of EOA/GOA of 0.85  0.18.P-PM
Indexed EOA increased from 0.28  1.0 to 0.98  0.28
cm2/m2. There was no P-PM in 181 (65.1%) patients; mod-
erate P-PM (iEOA 0.65 to 0.85 cm2/m2) was found in 76
(27.3%) patients, and severe P-PM (iEOA < 0.65
cm2/m2) in 21 (7.6%). Independent predictors of severe
P-PM were body surface area (P ¼ .00002) and LVOT di-
ameter (P ¼ .04). At a cutoff of 1.885 m2, body surface
area predicted severe P-PM with a sensitivity of 0.71 and
a specifity of 0.70 (odds ratio, 5.65; confidence intervals
[CI], 2.11-15.11; P ¼ .0004).
Patient characteristics for all patients, patients with no,
moderate, and severe P-PM are given in Table 2. The only
differences between groups are the significantly larger
body weight, body surface area, and body mass index in pa-
tients with P-PM.
Valve and hemodynamic characteristics according to the
groups are listed in Table 3. Patients with severe P-PM have
significantly lower EOA, stroke volume, and significantly
higher valve gradients in comparison with the groups with
moderate or no P-PM. P-PM was unrelated to annulusrdiovascular Surgery c Volume 145, Number 2 393
TABLE 2. Preprocedural parameters of patient group as a whole and divided into subgroups taking account of postprocedural P-PM
All No P-PM Moderate P-PM Severe P-PM P value
N 272 180 71 21
Sex male 81 (30%) 59 (33%) 17 (24%) 5 (24%) .32
Age (y) 80  8 80  7 78  11 79  6 .27
BW (kg) 72  16 69  13 77  19* 89  21*,y .0001
BSA (m2) 1.81  0.21 1.76  0.18 1.87  0.24* 2.00  0.24* .0001
BMI (kg $ m2) 26.8  5.6 25.6  4.5 28.3  6.3* 31.8  7.8* .0001
CAD 157 (58%) 99 (55%) 45 (63%) 13 (62%) .44
NYHA 3.30  0.49 3.33  0.48 3.25  0.49 3.26  0.54 .52
Log. EuroSCORE 37.8  20.2 38.4  20.2 35.8  19.2 39.9  24.0 .69
STS Mortality Score 18.5  15.2 18.1  14.7 18.8  15.4 21.4  18.9 .73
Creatine clearancez (mL $ min1) 52  24 48  21 60  30 59  24 .0019
ProBNP (ng/mL) 5.3  8.4 5.3  9.2 5.1  6.4 5.7  7.4 .940
Data are means SD or numbers (percent); Differences among groups were evaluated by Kruskal-Wallis test followed by the Dunn post hoc multiple comparisons and by c2 tests.
P-PM, Patient–prosthesis mismatch; BW, body weight; BSA, body surface area; BMI, body mass index; CAD, coronary artery disease; NYHA, New York Heart Association;
STS, The Society of Thoracic Surgeons; BNP, brain natriuretic peptide. *P<.05 versus no P-PM. yP<.05 versus moderate P-PM. zEstimated by Cockcroft-Gault formula.
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ses were implanted more frequently (72%) than in the
group with severe P-PM (52%; P ¼ .058).
Survival
Mean observation time was 14  10 month. The overall
30-day mortality was 4.0% (11 patients died). Survival at
1, 6, 12, 24, and 30 months was 96.0%, 85.8%, 82.3%,
65.7%, and 61%, respectively. Survival curves of patients
with severe or moderate P-PM versus patients without P-
PM are presented in Figure 1. Thirty-day survival of patients
without P-PM, with moderate P-PM, and with severe P-PM
was 96.0%, 97.3%, and 90.5%, respectively. Three-month
survival of patients without P-PM,withmoderate P-PM, and
with severe P-PM was 91%, 90%, and 66%, respectively
(P ¼ .0013). Only severe P-PM was associated with an in-
creased mortality within the first 3 months (P ¼ .0013).TABLE 3. Valve characteristic and hemodynamic data of patient group as
PPM
All No P-PM
AVannulus (mm) 21.8  1.6 21.9  1.6
Prosthessis 26 mm 182 (67%) 129 (72%)
EOA (cm2) 1.8  0.4 2.0  0.4
iEOA (cm2 $ m2) 0.98  0.26 1.12  0.21
LVOT SV (mL) 51  19 55  19
LVOT CO (L $ min1) 3.7  1.4 4.0  1.5
HR (beats/min) 76  17 75  17
LVEDV biplane (mL) 69  32 69  31
EF (%) 59  15 59  15
DPmax (mm Hg) 10.5  5.8 9.5  5.0
DPmean (mm Hg) 5.4  3.0 4.9  2.5
LVOT Vmax (m $ s1) 0.98  0.28 0.99  0.28
Data are means standard deviation. Differences among groups were evaluated by Kruska
thesis mismatch; AVannulus, aortic valve annulus diameter; iEOA, indexed effective orifice
ventricular outflow tract diameter and mean blood flow velocity; HR, heart rate; LVEDV,
transvalvular pressure gradient; DdPmean, change in mean transvalvular pressure gradien
394 The Journal of Thoracic and Cardiovascular SurgThis difference was maintained until 12 months
(P¼ .039) but leveled off thereafter (P¼ .19 at 30 months).
The group of patients with severe P-PM (n¼ 21) was an-
alyzed in more detail (Table 4). The only significant differ-
ence between the 14 survivors and the 7 nonsurvivors was
a greater peak transvalvular pressure gradient in the nonsur-
vivors (19.8 10.8 vs 11.5 5.5 mm Hg; P¼ .02). Within
the small group of patients with severe P-PM, 14 had a peak
pressure gradient greater than 10 mm Hg, which was asso-
ciated with a survival rate of 48% at 3 months, whereas all
of the 7 patients with a peak pressure gradient less than 10
mm Hg survived (P¼ .029). Also, 5 of the patients with se-
vere P-PM had an LVEF less than 50%, which tended to be
associated with a lower survival at 3 months than LVEF
greater than 50% (40% vs 75%; P ¼ .051). Between sur-
vivors and nonsurvivors in this group, there was no differ-
ence in EuroSCORE (35.7  20.4 vs 48.4  29.7;a whole and divided into sub-groups taking account of post-procedural
Moderate P-PM Severe P-PM P value
21.6  1.7 21.8  1.5 .46
42 (59%) 11 (52%) .056
1.4  0.2* 1.2  0.1* .0001
0.75  0.06 0.59  0.04 ND
44  15* 38  11* .0001
3.3  1.2* 2.9  0.8* .0001
76  18 78  15 .81
67  35 70  33 .45
59  14 58  19 .99
11.8  6.1* 14.3  8.4* .0002
6.3  3.4* 7.5  4.1* .0001
0.96  0.28 0.98  0.27 .59
l-Wallis test followed by Dunn’s post hoc multiple comparisons. P-PM, Patient–pros-
area; LVOT SV and LVOT CO, stroke volume and cardiac output calculated from left
left ventricular end-diastolic volume; EF, ejection fraction; DdPmax, change in peak
t; LVOT Vmax, peak LVOT blood flow velocity. *P<.05 versus no P-PM.
ery c February 2013
FIGURE 1. Kaplan-Meier survival curves for patients without P-PM
(iEOA> 0.85), with moderate P-PM (iEOA 0.65-0.85), and with severe
P-PM (iEOA<0.65). Censored patients are represented by vertical marks.
Only severe P-PMwas associated with increased early mortality within the
first 3 months after TAVI. This effect was confirmed in a multivariate anal-
ysis. The difference in survivals persisted for 1 year and leveled off there-
after. P values were derived from the log–rank test nd all pairwise
comparisons by Holm-Sidak (adjustedP¼ .0014 and .009 for severe versus
no and moderate P-PM at 3 months and .037 and .13 at 12 month, respec-
tively). P-PM, Patient–prosthesis mismatch; iEOA, indexed effective ori-
fice area; TAVI, transcatheter aortic valve implantation.
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DP ¼ .26) or in Society of Thoracic Surgeons score (17.4 
12.6 vs 29.3  26.9; P ¼ .43).
Additionally, postprocedural LVEF, LVESV, and heart
rate show significant impact on 30-month survival. Survival
was decreased in patients with an EF less than 50% than in
patients with EF greater than 50% (78%, 47%, and 37% vsTABLE 4. Echocardiographic findings in patients with severe P-PM
(iEOA<0.65 cm2/m2)
Variable Survivors Nonsurvivors P value
N 14 7
EF (%) 61  16 51  23 .34
LVEDV (mL) 64  26 84  46 .39
LVESV (mL) 26  17 46  40 .34
LVOT SV (mL) 35.4  9.1 42.3  13.8 .28
EOA (cm2) 1.16  0.08 1.20  0.16 .68
iEOA (cm2/m2) 0.59  0.04 0.58  0.06 .47
dPmax (mm Hg) 11.5  5.5 19.8  10.8 .02
dPmean (mm Hg) 6.3  2.6 9.9  5.5 .07
EF and LV volumes were calculated by the biplane method. All data are means 
standard deviation. P values are derived from unpaired t tests. P-PM, Patient–prosthe-
sis mismatch; iEOA, indexed effective orifice area; EF, ejection fraction; LVEDV, left
ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume;
EOA, effective orifice area; dPmax, peak transvalvular pressure gradient; dPmean,
mean transvalvular pressure gradient.
The Journal of Thoracic and Ca82%, 71%, and 71% at, respectively, 12, 24, and 30
months; P ¼ .027) (Figure 2). Also, patients with a LVESV
greater than 35 mL show reduced survival compared with
those with an LVESV less than 35 mL (74%, 46%, and
37% vs 85%, 72%, and 72% at, respectively, 12, 24, and
30 months; P ¼ .002). Postprocedural heart rate greater
than 80 beats/min had a negative impact on survival
(76%, 53%, and 49% vs 86%, 75%, and 70% at, respec-
tively, 12, 24, and 30 months; P ¼ .005). Postprocedural
LVEDV, transvalvular peak, or the mean pressure gradients
had no significant impact on survival. In the multivariate
analyses, severe P-PM and heart rate were confirmed as in-
dependent predictors of 3-month survival whereas heart rate
and serum creatinine concentration were associated with
30-month survival (Table 5). In contrast, LVEF and LVESV
were not confirmed as independent predictors of 30-month
survival.
DISCUSSION
Our study demonstrates that quantitative TEE data ac-
quired during the intraprocedural course of TAVI are of in-
terest also for postprocedural risk stratification and decision
making. The major finding of our study is that postproce-
dural severe P-PM has a marked independent impact on
3-month survival in high-risk patients undergoing TAVI.
This effect is even more pronounced when severe P-PM is
combined with a transvalvular peak pressure gradient
greater than 10 mm Hg. In addition, serum creatinine con-
centration and postprocedural heart rate, LVEF, and LVESV
were associated with survival, but the contribution of LVEF
and LVESV was not confirmed in the multivariate analysis.
Prevalence of severe P-PM in our TAVI group was 7.6%
and thus comparable with that in patients undergoing AVR
or TAVI (2%-13%).3,14-17 Blais,3 Rabus,17 and their associ-
ates identified severe P-PM (iEOA<0.65 cm2/m2) as an in-
dependent predictor of short-term mortality among patients
undergoing AVR. Concurrently, in our group severe P-PM
also had a significant effect on short-term survival. How-
ever, beyond the critical period of 3 months, the prognosis
of patients with severe P-PM was comparable with that of
patients with iEOA greater than 0.65 cm2/m2. Additional
analysis of patients with severe P-PM shows that the com-
bination of severe P-PM with a peak transvalvular pressure
gradient greater than 10 mm Hg (which occurred in our 14
patients) was particularly detrimental, resulting in
a 3-month survival of only 48%, whereas all 7 of the pa-
tients with a lower pressure gradient survived this early pe-
riod. Increased pressure gradients result in increased LV
workload, which may explain their impact on mortality. Al-
though the average peak pressure gradient in this subgroup
was only moderately increased (17.6  8.5 mm Hg), it is
necessary to keep in mind that it was measured during
steady state at rest and may markedly increase during
even moderate physical exertion. Despite the low numbersrdiovascular Surgery c Volume 145, Number 2 395
FIGURE 2. Kaplan-Meier survival curves for patients with ejection fraction (EF) greater than 50% versus less than 50% (left panel) and for patients with
left ventricular end-systolic volume (LVESV) less than 35 mL versus greater than 35 mL (right panel). Cutoff values for risk stratification were selected from
receiver operating characteristics curves. Censored patients are represented by vertical marks. P values were derived from log–rank tests. The association of
EF and LVESV with survival was, however, not confirmed in the multivariate analysis.
Acquired Cardiovascular Disease Kukucka et al
A
C
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of severe P-PM and change in peak pressure gradient
greater than 10 mm Hg (14 patients), these findings may
have immediate clinical impact. Therefore, theoretically,
an attempt to increase postprocedural iEOA might be con-
sidered (ie, by redilatation of the implanted valve or by sur-
gical AVR). Especially for the latter decision, the risks of
this intervention must be carefully weighed against the an-
ticipated benefits. Alternatively, after recovery from the
procedure, pressure gradients could be measured during
stress echocardiography and further decisions based on
these results. However, before an unequivocal clinical rec-
ommendation can be given, more studies on the incidence
of severe P-PM with or without accompanying increased
pressure gradients after TAVI and its impact on survival
are needed.
Walther and colleagues18 used the expected EOA pro-
vided by valve manufacturers divided by body surfaceTABLE 5. Results of multivariate Cox regression proportional
hazards model






P-PM 4.41 (1.71-11.41) .002 1.25 (0.52-2.97) .62
Heart rate
(beats/min)
1.03 (1.004-1.06) .023 1.02 (1.01-1.04) .007
Creatinine
(mg/dL)
1.22 (0.71-2.12) .47 1.66 (1.15-2.39) .006
LVEF (%) 1.02 (0.97-1.07) .43 1.0 (0.98-1.03) .87
LVESV (mL) 1.01 (0.99-1.04) .24 1.01 (0.99-1.02) .46
Here only selected results are shown. Additional covariates in the multivariate model
without near significant contribution to survival were peripheral vascular disease,
chronic obstructive pulmonary disease, pulmonary hypertension, diabetes, coronary
artery disease, and sex. Heart rate, LVEF, and LVESV were obtained postprocedur-
ally. HR, Hazard ratio; CI, 95% confidence interval; P-PM, patient–prosthesis mis-
match; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic
volume.
396 The Journal of Thoracic and Cardiovascular Surgand identified expected moderate P-PM to be a risk factor
for short- and long-term mortality in patients after AVR.
In our study we used measured actual EOA and show that
the moderate P-PM has no impact on survival. Pibarot
and Dumesnil4 suggested an algorithm to avoid P-PM after
AVR that relates the expected EOA of the valve prosthesis
to the patient’s body surface area. After this procedure, nei-
ther severe nor moderate P-PM would have been expected
in any of our patients. However, this algorithm is not appli-
cable for TAVI because of the unpredictable impact of the
native valve and its calcification on postprocedural EOA.
Therefore, we measured actual postprocedural EOA in the
present study and found the reported incidence for P-PM.
Interestingly, preprocedural annulus size had no impact
and LVOT diameter only a small impact on the incidence
of severe P-PM. In contrast, body surface area greater
than 1.885 m2 independently predicted severe P-PM with
satisfactory sensitivity (0.71) and specifity (0.70).
The adverse impact of P-PMwas more evident in patients
with impaired LV function.3 In our study, LV function im-
proved immediately after TAVI, which may be due to the
lack of an adverse impact of cardiopulmonary bypass and
ischemia and reperfusion that occur during conventional
AVR.19 Yet, a considerable number of our TAVI patients
(27%) still had a postprocedural LVEF less than 50%,
which had a marked effect on 30-month survival. In addi-
tion, also within the subgroup of patients with severe
P-PM, combination with LVEF less than 50% presented
with a strong trend for decreased 3-month survival
(P¼ .051). Depressed postprocedural LV function could re-
sult from more pronounced myocardial remodeling,
namely, fibrosis,20 or decreased systemic arterial compli-
ance,21 which are not relieved by the intervention. Similarly
to LVEF, LVESValso influenced the patient’s survival. That
is to be expected because both parameters are strongly de-
termined by LV systolic function. Although the impact ofery c February 2013
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DLVEF and LVESV on survival was not confirmed to be in-
dependent from other risk factors in the multivariate analy-
sis, we consider this finding noteworthy because these
parameters are easily available to the attending physician.
In contrast, low LVEDV may indicate diminished myocar-
dial compliance owing to fibrosis, whereas high LVEDV
may be due to cardiac dilatation in the course of developing
heart failure. Inasmuch as both conditions would be ex-
pected to affect survival after TAVI, it is not surprising
that no dependence of survival on LVEDV was detected
in this study.
CONCLUSIONS
In conclusion, periprocedural TEE during TAVI allowed
identification of risk factors that affect survival in these
high-risk patients. Namely, severe P-PM occurred in
7.6% of patients and was associated with considerably in-
creased early mortality. Combination of this condition
with an increased transvalvular peak pressure gradient
greater than 10 mm Hg even worsened this effect. Although
more studies are needed to substantiate such recommenda-
tions, this small subgroup of patients might benefit from im-
mediate reintervention, either by redilatation or even by
conversion to open cardiac surgery. Finally, it is important
to stress that the analysis of echocardiographic data after
TAVI and their impact on survival represents only one
view of the multitask problem presented by these high-
risk patients.
The other members of our TAVI team are Semih Buz, MD,
Thorsten Drews, MD, Giuseppe D’Ancona, MD, PhD, Christoph
Klein, MD, Katrin Sch€afer, Ekatarina Ivanitskaia-K€uhn, and
Natalia Solowjowa, MD. We thank Anne Gale for editorial
assistance.
References
1. Schueler R, Hammerstingl C, Sinning JM, Nickenig G, Omran H. Prognosis of
octogenarians with severe aortic valve stenosis at high risk for cardiovascular
surgery. Heart. 2010;96:1831-6.
2. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation.
1978;58:20-4.
3. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of valve
prosthesis-patient mismatch on short-term mortality after aortic valve replace-
ment. Circulation. 2003;108:983-8.
4. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient
mismatch in the aortic valve position and its prevention. JAmColl Cardiol. 2000;
36:1131-41.The Journal of Thoracic and Ca5. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L, et al. Early
experience with percutaneous transcatheter implantation of heart valve prosthe-
sis for the treatment of end-stage inoperable patients with calcific aortic stenosis.
J Am Coll Cardiol. 2004;43:698-703.
6. Pasic M. Transapical aortic valve implantation in 175 consecutive patients: ex-
cellent outcome in very high-risk patients. J Am Coll Cardiol. 2010;56:813-20.
7. Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, et al. Per-
cutaneous transarterial aortic valve replacement in selected high-risk patients
with aortic stenosis. Circulation. 2007;116:755-63.
8. Pasic M, Buz S, Dreysse S, Drews T, Unbehaun A, Klein C, et al. Transapical
aortic valve implantation in 194 patients: problems, complications, and solu-
tions. Ann Thorac Surg. 2010;90:1463-9; discussion 1469-70.
9. Moss RR, Ivens E, Pasupati S, Humphries K, Thompson CR, Munt B, et al. Role
of echocardiography in percutaneous aortic valve implantation. J Am Coll Car-
diol. 2008;1:15-24.
10. Pasic M, Dreysse S, Drews T, Buz S, Unbehaun A, Kukucka M, et al. Improved
technique of transapical aortic valve implantation: ‘‘the Berlin addition.’’ Ann
Thorac Surg. 2010;89:2058-60.
11. Walther T, Dewey T, Borger MA, Kempfert J, Linke A, Becht R, et al. Transap-
ical aortic valve implantation: step by step. Ann Thorac Surg. 2009;87:276-83.
12. Shanewise JS, Cheung AT, Aronson S, Stewart WJ, Weiss RL, Mark JB, et al.
ASE/SCA guidelines for performing a comprehensive intraoperative multiplane
transesophageal echocardiography examination: recommendations of the Amer-
ican Society of Echocardiography Council for Intraoperative Echocardiography
and the Society of Cardiovascular Anesthesiologists Task Force for Certification
in Perioperative Transesophageal Echocardiography. J Am Soc Echocardiogr.
1999;12:884-900.
13. Pasic M, Unbehaun A, Dreysse S, Buz S, Drews T, KukuckaM, et al. Transapical
aortic valve implantation after previous aortic valve replacement: clinical proof
of the ‘‘valve-in-valve’’ concept. J Thorac Cardiovasc Surg. 2011 Aug;142(2):
270-7.
14. Kalavrouziotis D, Rodes-Cabau J, Bagur R, Doyle D, De Larochelliere R,
Pibarot P, et al. Transcatheter aortic valve implantation in patients with se-
vere aortic stenosis and small aortic annulus. J Am Coll Cardiol. 2011;58:
1016-24.
15. Howell NJ, Keogh BE, Barnet V, Bonser RS, Graham TR, Rooney SJ, et al. Pa-
tient-prosthesis mismatch does not affect survival following aortic valve replace-
ment. Eur J Cardiothorac Surg. 2006;30:10-4.
16. Jilaihawi H, Chin D, Spyt T, Jeilan M, Vasa-Nicotera M, Bence J, et al. Prosthe-
sis-patient mismatch after transcatheter aortic valve implantation with the
Medtronic-Corevalve bioprosthesis. Eur Heart J. 2010;31:857-64.
17. Rabus MB, Kirali K, Kayalar N, Mataraci I, Yanartas M, Ulusoy-Bozbuga N,
et al. Effects of patient-prosthesis mismatch on postoperative early mortality in
isolated aortic stenosis. J Heart Valve Dis. 2009;18:18-27.
18. Walther T, Rastan A, Falk V, Lehmann S, Garbade J, Funkat AK, et al. Patient
prosthesis mismatch affects short- and long-term outcomes after aortic valve re-
placement. Eur J Cardiothorac Surg. 2006;30:15-9.
19. Clavel MA,Webb JG, Pibarot P, Altwegg L, Dumont E, Thompson C, et al. Com-
parison of the hemodynamic performance of percutaneous and surgical biopros-
theses for the treatment of severe aortic stenosis. J Am Coll Cardiol. 2009;53:
1883-91.
20. Weidemann F, Herrmann S, Stork S, NiemannM, Frantz S, Lange V, et al. Impact
of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circu-
lation. 2009;120:577-84.
21. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D, et al. Reduced
systemic arterial compliance impacts significantly on left ventricular afterload
and function in aortic stenosis: implications for diagnosis and treatment. J Am
Coll Cardiol. 2005;46:291-8.rdiovascular Surgery c Volume 145, Number 2 397
